摘要
目的探讨采用左氧氟沙星对初治涂阳肺结核的疗效。方法将2016年1月—5月在结核病防治科登记治疗的120例初治涂阳肺结核患者随机分为3组,分别以A组(左氧氟沙星组)4HRZEL/2HR,B组(强化期延长方案组)4HRZE/2HR,C组(标准方案组)2HRZE/4HR方案进行6个月抗结核治疗。结果 3组2月末痰培养阴转率分别为91.7%,77.1%,82.9%,5月末痰培养阴转率分别为100.0%,91.4%,85.7%,6月末痰培养阴转率分别为100.0%,94.3%,88.6%,3组间痰菌阴转率差异无统计学意义(P>0.05)。3组6月末病灶明显吸收率分别为80.6%,54.3%,45.7%,A组明显高于B组和C组(P<0.05)。3组6月空洞闭合率分别为95.0%,75.0%,62.5%,A组高于C组(P<0.05),但与B组比较差异无统计学意义(P=0.077)。结论 4HRZEL/2HR治疗方案可提高初治涂阳肺结核治愈率和病灶吸收率,但仍需进一步研究。
Objective To investigate the curative effect of different chemotherapy regimens in the treatment of newlydiagnosed smear positive pulmonary tuberculosis. Methods A total of 120 patients with newly diagnosed smear positivepulmonary tuberculosis were randomly divided into 3 groups from January 2016 to May 2016, group A（levofloxacin group）4HRZEL/2HR, group B（extended period group） 4HRZE/2HR, group C（standard group） 2HRZE/4HR with 6 months of antituberculosis scheme. Results Three groups of at the end of two months sputum culture negative conversion rate were 91.7%,77.1%, 82.9%, at the end of five months sputum culture negative conversion rate were 100.0%, 91.4%, 85.7%, at the end ofsix months sputum culture negative conversion rate were 100.0%, 94.3%, 88.6%. There was no significant difference betweenthe three groups in sputum negative conversion rate（P〉0.05）. Three groups at the end of six months, the absorption rate oflesions was 80.6%, 54.3%, 45.7%, group A was significantly higher than that of group B and group C（P〈0.05）. The closurerate of the three groups was 95.0%, 75.0%, 62.5% at the end of six months, group A was higher than group C（P〈0.05）.However, there was no significant difference between the group B and group A（P=0.077）.Conclusion 4HRZEL/2HRtreatment can improve the cure rate and the absorption rate of smear positive pulmonary tuberculosis, but it still needs furtherresearch.
出处
《中国热带医学》
CAS
2017年第4期424-426,共3页
China Tropical Medicine
关键词
肺结核
初治
涂阳
标准化疗方案
耐药
左氧氟沙星
pulmonary tuberculosis
initial treatment
smear positive
standard chemotherapy regimen
drug resistance
levofloxacin
